Executive interview – Paion

Published on 10 December 2018

CEO Dr Wolfgang Söhngen provides an overview of Paion’s core technology, Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anaesthetic. He also discusses the group’s strategy including partnership deals with Cosmo and Mundipharma and the path to market for Paion’s products.

Share this with friends and colleagues

You may also be interested in these

pacla medical

Pacla Medical – executive interview

TMT
28 June 2022
cantargia

Cantargia – executive interview

Healthcare
24 June 2022
Vantage.jpg

Vantage: James Thorne on the smaller companies’ effect

Investment companies
24 June 2022

Vantage: Randy Baron on buying growth using the principles of a value investor

Investment companies
21 June 2022